Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The widespread use of Nivolumab results in an increasing number of side effects and adverse events. Herein, we evaluated the impact of Nivolumab on crude and normalized pulmonary artery diameter (PAD).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Chemother Pharmacol

Title: Cancer chemotherapy and pharmacology

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 1432-0843

ISSN (Print): 0344-5704

Publication date (Electronic): Oct 2020

Volume: 86

Issue: 4

Affiliations

[1 ] Thoracic Surgery Department, Cochin Hospital, AP-HP.Center-University of Paris, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. ludovic.fournel@aphp.fr.

[2 ] Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, AP-HP.Center-University of Paris, Paris, France. ludovic.fournel@aphp.fr.

[3 ] Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Cochin Hospital, AP-HP.Center-University of Paris, Paris, France.

[4 ] Oncology Department, Cochin Hospital, AP-HP.Center-University of Paris, Paris, France.

[5 ] Thoracic Surgery Department, Cochin Hospital, AP-HP.Center-University of Paris, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France.

[6 ] Radiology Department, Cochin Hospital, AP-HP.Center-University of Paris, Paris, France.

[7 ] Pathology Department, Cochin Hospital, AP-HP.Center-University of Paris, Paris, France.

[8 ] Respiratory Medicine and Thoracic Oncology Department, Cochin Hospital, AP-HP.Center-University of Paris, Paris, France.

[9 ] Biology and Immunology Department, AP-HP.Center, University of Paris, Paris, France.

[10 ] INSERM U-119, UNICAEN, University of Caen-Normandy, Caen, France.

Article

Publisher Item ID: 10.1007/s00280-020-04142-9

DOI: 10.1007/s00280-020-04142-9

PubMed ID: 32936316

SO-VID: 3b363db6-6323-48db-afa4-3699daaff962

History

Keywords: Nivolumab,Pulmonary artery hypertension,Immune check-point inhibitors,Lung cancer

Data availability:

Keywords: Nivolumab, Pulmonary artery hypertension, Immune check-point inhibitors, Lung cancer

Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.

Read this article at

Abstract

Related collections

Negative Pressure Wound Therapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 114

Cited by 6